CEMMA and LipoCoat Announce Partnership for Coated CVC Catheter
Central Venous Catheter Co-Development
Jasper van Weerd
April 20, 2022
Introduction
CEMMA Medical and LipoCoat BV announce a co-development partnership for central venous catheters. CEMMA & LipoCoat CVC CollaborationTaipei / Enschede, April 20, 2022 — CEMMA Medical and LipoCoat co-developed a coated Central Venous Catheter (CVC) prototype demonstrating a 2-log reduction in bacterial attachment without antibiotics.
CEMMA & LipoCoat CVC CollaborationTaipei / Enschede, April 20, 2022 — CEMMA Medical and LipoCoat co-developed a coated Central Venous Catheter (CVC) prototype demonstrating a 2-log reduction in bacterial attachment without antibiotics.
Pre-clinical CVC bacterial attachment study data
Jasper van Weerd
CEO / Founder
Jasper van Weerd is CEO of Lipocoat and founder of the LipoCoat coating technology, translating lipid-based science into products that improve the safety, comfort and performance of medical devices.
Updates
Also interesting
LipoCoat and SonoCoat have earned recognition from leading institutions and regulatory bodies. Our coatings meet the highest standards for biocompatibility and clinical efficacy.
Publication
SonoCoat® Technology Featured in Scientific Publications
Four independent peer-reviewed studies have evaluated SonoCoat®, from EUS-FNA needles to prostate brachytherapy. What each one tested, and what it found.
Document
When the Needle Disappears: SonoCoat® in Three Clinical Applications
Real-time ultrasound guidance is now standard for CVC placement, yet needles still vanish at steep insertion angles. What SonoCoat® changes in vascular access, biopsy and regional anesthesia.
News
TFDA Approves CEMMA and LipoCoat Coated Antifouling CVC Catheter
Taiwan FDA approves CEMMA and LipoCoat co-developed coated antifouling central venous catheter for critical care.